Literature DB >> 20237129

Cerebrospinal fluid chitinase 3-like 1 levels are associated with conversion to multiple sclerosis.

Manuel Comabella1, Marta Fernández, Roland Martin, Stephanie Rivera-Vallvé, Eva Borrás, Cristina Chiva, Eva Julià, Alex Rovira, Ester Cantó, Jose Carlos Alvarez-Cermeño, Luisa María Villar, Mar Tintoré, Xavier Montalban.   

Abstract

In most patients with multiple sclerosis, the disease initiates with a first attack or clinically isolated syndrome. At this phase, magnetic resonance imaging is an important predictor of conversion to multiple sclerosis. With the exception of oligoclonal bands, the role of other biomarkers in patients with clinically isolated syndrome is controversial. In the present study, we aimed to identify proteins associated with conversion to multiple sclerosis in patients with clinically isolated syndrome. We applied a mass spectrometry-based proteomic approach (isobaric labelling) to previously collected pooled cerebrospinal fluid samples from patients with clinically isolated syndrome, who subsequently converted to clinically definite multiple sclerosis (n=30) and patients who remained as having clinically isolated syndrome (n=30). Next, three of the most represented differentially expressed proteins, i.e. ceruloplasmin, vitamin D-binding protein and chitinase 3-like 1 were selected for validation in individual cerebrospinal fluid samples by enzyme-linked immunosorbent assay. Only chitinase 3-like 1 was validated and cerebrospinal fluid levels were increased in patients who converted to clinically definite multiple sclerosis compared with patients who continued as clinically isolated syndrome (P=0.00002) and controls (P=0.012). High cerebrospinal fluid levels of chitinase 3-like 1 significantly correlated with the number of gadolinium enhancing lesions and the number of T2 lesions observed in brain magnetic resonance imaging scans performed at baseline, and were associated with disability progression during follow-up and shorter time to clinically definite multiple sclerosis (log-rank P-value=0.003). Cerebrospinal fluid chitinase 3-like 1 levels were also measured in a second validation clinically isolated syndrome cohort and found to be increased in patients who converted to multiple sclerosis compared with patients who remained as having clinically isolated syndrome (P=0.018). Our results indicate that patients who will convert to clinically definite multiple sclerosis could be distinguished from those patients who will remain as clinically isolated syndrome by proteomic analysis of cerebrospinal fluid samples. Although protein levels are also increased in other disorders characterized by chronic inflammation, chitinase 3-like 1 may serve as a prognostic biomarker for conversion to multiple sclerosis and development of disability which may help to improve the understanding of the aetiopathogenesis in the early stages of multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20237129     DOI: 10.1093/brain/awq035

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  75 in total

1.  A complex of nuclear factor I-X3 and STAT3 regulates astrocyte and glioma migration through the secreted glycoprotein YKL-40.

Authors:  Sandeep K Singh; Reetika Bhardwaj; Katarzyna M Wilczynska; Catherine I Dumur; Tomasz Kordula
Journal:  J Biol Chem       Date:  2011-09-27       Impact factor: 5.157

Review 2.  Body fluid biomarkers for multiple sclerosis--the long road to clinical application.

Authors:  Charlotte E Teunissen; Arjan Malekzadeh; Cyra Leurs; Claire Bridel; Joep Killestein
Journal:  Nat Rev Neurol       Date:  2015-09-22       Impact factor: 42.937

3.  YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease.

Authors:  Rebecca Craig-Schapiro; Richard J Perrin; Catherine M Roe; Chengjie Xiong; Deborah Carter; Nigel J Cairns; Mark A Mintun; Elaine R Peskind; Ge Li; Douglas R Galasko; Christopher M Clark; Joseph F Quinn; Gina D'Angelo; James P Malone; R Reid Townsend; John C Morris; Anne M Fagan; David M Holtzman
Journal:  Biol Psychiatry       Date:  2010-11-15       Impact factor: 13.382

Review 4.  The emerging role of vitamin D binding protein in multiple sclerosis.

Authors:  Giulio Disanto; Sreeram V Ramagopalan; Andrea E Para; Lahiru Handunnetthi
Journal:  J Neurol       Date:  2010-11-02       Impact factor: 4.849

Review 5.  Blood Biomarkers as Outcome Measures in Inflammatory Neurologic Diseases.

Authors:  Nabil K El Ayoubi; Samia J Khoury
Journal:  Neurotherapeutics       Date:  2017-01       Impact factor: 7.620

6.  CSF-PR 2.0: An Interactive Literature Guide to Quantitative Cerebrospinal Fluid Mass Spectrometry Data from Neurodegenerative Disorders.

Authors:  Astrid Guldbrandsen; Yehia Farag; Ann Cathrine Kroksveen; Eystein Oveland; Ragnhild R Lereim; Jill A Opsahl; Kjell-Morten Myhr; Frode S Berven; Harald Barsnes
Journal:  Mol Cell Proteomics       Date:  2016-11-27       Impact factor: 5.911

Review 7.  The utility of cerebrospinal fluid analysis in patients with multiple sclerosis.

Authors:  Martin Stangel; Sten Fredrikson; Edgar Meinl; Axel Petzold; Olaf Stüve; Hayrettin Tumani
Journal:  Nat Rev Neurol       Date:  2013-03-26       Impact factor: 42.937

Review 8.  Proteomic Approaches to Decipher Mechanisms Underlying Pathogenesis in Multiple Sclerosis Patients.

Authors:  Vaibhav Singh; Ajai Tripathi; Ranjan Dutta
Journal:  Proteomics       Date:  2019-06-21       Impact factor: 3.984

9.  The chemokine CXCL13 is a prognostic marker in clinically isolated syndrome (CIS).

Authors:  Johannes Brettschneider; Anne Czerwoniak; Makbule Senel; Lubin Fang; Jan Kassubek; Elmar Pinkhardt; Florian Lauda; Tamara Kapfer; Sarah Jesse; Vera Lehmensiek; Albert C Ludolph; Markus Otto; Hayrettin Tumani
Journal:  PLoS One       Date:  2010-08-05       Impact factor: 3.240

10.  Discovery of novel disease-specific and membrane-associated candidate markers in a mouse model of multiple sclerosis.

Authors:  Laura F Dagley; Nathan P Croft; Ruth Isserlin; Jonathan B Olsen; Vincent Fong; Andrew Emili; Anthony W Purcell
Journal:  Mol Cell Proteomics       Date:  2013-12-20       Impact factor: 5.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.